NSCLC research is taking aim at chemotherapy
Now enrolling:
The TROPION-Lung07 study for adults with advanced or metastatic non-small cell lung cancer (NSCLC).
The TROPION-Lung07 study for adults with advanced or metastatic non-small cell lung cancer (NSCLC).
This study is investigating Dato-DXd (in combination with pembrolizumab, a standard therapy, with or without platinum-based chemotherapy) to find out how well it works to slow tumor growth in patients with advanced or metastatic NSCLC.
Doctors will compare the study drug combination of Dato-DXd plus pembrolizumab with or without platinum-based chemotherapy to pembrolizumab plus pemetrexed and platinum-based chemotherapy. Dato-DXd is a study drug, which is a drug that is not yet approved for use by the general public. Pembrolizumab is an approved drug used for the treatment of patients with advanced or metastatic NSCLC.
To be eligible for this study, you must:
This is not a complete list of study requirements. The study doctor will review the full requirements with you.
Participants will be in the study for approximately 36 months, which includes a safety follow-up period after the last dose of study drug.
These tests and assessments will help study doctors and study staff determine if you can participate in this study.
*These tests and procedures will occur during the tissue screening period. It may be possible to use a recent tumor biopsy, if it meets certain criteria.
These tests and assessments will help study doctors and study staff monitor your health while you are receiving the study drug as part of this study.
Your study drug will be administered in cycles, with each cycle lasting 21 days. You will be in this study for a minimum of one cycle and can continue for future cycles unless your disease gets worse, you don’t feel well, you and your doctor decide to stop, or you reach 35 cycles.
Before your scheduled study drug, you will be given certain premedications by your study doctor to take prior to each infusion. Premedications are medications that help to lessen the occurrence and severity of certain side effects associated with each of the study drugs.
Once you stop receiving the study drug, you will have an end of treatment visit immediately and a follow-up visit 30 days after the last dose of the study drug.
You may still continue to participate in this clinical study even if you choose not to participate in any optional tests or procedures.
If you're interested in learning more about the TROPION-Lung07 study, including potential risks and benefits of participation, you can find additional details at CTGOV.